Literature DB >> 6606065

Transfer factor in restoration of cell mediated immunity in lung cancer patients.

T Fujisawa, Y Yamaguchi, H Kimura.   

Abstract

We studied the transfer factor (TF) with regard to in vivo and in vitro restoration of cell mediated immunity (CMI) in lung cancer patients. Twenty-eight lung cancer patients who had undergone resection were the recipients and 30 household contact family members with a positive reactivity to lung cancer extract were the donors of TF. Immunologic status was evaluated by delayed type cutaneous hypersensitivity (DTH), peripheral T lymphocyte number, PHA lymphocyte blastogenesis, serum blocking activity (SBA) and leucocyte adherence inhibition (LAI) test. When TF was administered twice subcutaneously to the patients, there was a statistically significant restoration or augmentation of DTH, PHA lymphocyte blastogenesis and abrogation of SBA, particularly in patients with suppressed CMI. These results suggest that it was the TF obtained from relatives of lung cancer patients with positive reactivity to tumor associated antigens restored or augmented tumor specific and nonspecific CMI in these lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606065     DOI: 10.1007/bf02469511

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  19 in total

1.  The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes.

Authors:  H S LAWRENCE
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

2.  Transfer factor in the treatment of a case of chronic mucocutaneous candidiasis.

Authors:  M L Schulking; W H Adler; W A Altemeier; E M Ayoub
Journal:  Cell Immunol       Date:  1972-04       Impact factor: 4.868

3.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

4.  In vitro transfer of cellular immunity against nasopharyngeal carcinoma using transfer factor from donors with Epstein-Barr virus antibody activity.

Authors:  L J Brandes; G J Goldenberg
Journal:  Cancer Res       Date:  1974-11       Impact factor: 12.701

5.  The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma.

Authors:  A F LoBuglio; J A Neidhart; R W Hilberg; E N Metz; S P Balcerzak
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

6.  Transfer factor deficiency response--a mechanism of anergy in Boeck's sarcoid.

Authors:  H S Lawrence; B Zweiman
Journal:  Trans Assoc Am Physicians       Date:  1968

7.  Comparison of serum blocking factors on leucocyte adherence inhibition and PHA lymphocyte blastogenesis in breast cancer patients.

Authors:  T Fujisawa; R H Yonemoto; S R Waldman
Journal:  Jpn J Surg       Date:  1981

8.  Human transfer factors: structural properties suggested by HPRP chromatography and enzymatic sensitivities.

Authors:  D R Burger; A A Vandenbark; W Dunnick; W Kraybill; G D Daves; R M Vetto
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

9.  Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory responses to therapy with transfer factor.

Authors:  A S Levin; L E Spitler; D P Stites; H H Fudenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

10.  Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients.

Authors:  T Fujisawa; S R Waldman; R H Yonemoto
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

View more
  1 in total

1.  Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung.

Authors:  T Fujisawa; Y Yamaguchi; H Kimura; M Arita; M Shiba; M Baba
Journal:  Jpn J Surg       Date:  1984-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.